Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $11.64M rose 31.1% year over year, ahead of the +9.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 15.7% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Stock-based compensation amounted to 4.5% of revenue in FY2025, down 2.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +31.1% holds above the trailing-twelve-month pace of +9.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 30.69M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +5.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.69M | +0.0% |
| FY2024 | 2024-12-31 | 30.69M | +13.1% |
| FY2023 | 2023-12-31 | 27.15M | +8.1% |
| FY2022 | 2022-12-31 | 25.12M | -0.2% |
| FY2021 | 2021-12-31 | 25.17M | — |
Stock-Based Compensation vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's LTM Jun 2026 stock-based compensation of $35.76M is the 5th largest of the 10 companies compared; the peer median is $34.27M.
- Its year-over-year change of +9.2% is the 5th highest of 10, against a peer median of +8.7%.
- Stock-based compensation amounts to 4.3% of revenue for KNSA, versus a peer median of 99.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.91M | -7.8% | +19.9% | 717.6% | |
| LTM Sep 2026 | $50.3M | +35.9% | +74.2% | 55.6% | |
| LTM Mar 2026 | $41.12M | +24.3% | +9.7% | 17.7% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Jun 2026 | $35.76M | +9.2% | +6.9% | 4.3% | |
| LTM Jun 2026 | $34.27M | +82.5% | +146.7% | 1800.0% | |
| LTM Mar 2026 | $13.96M | +64.9% | +21.7% | 23652.5% | |
| LTM Mar 2026 | $12.05M | -2.1% | -6.3% | 144.0% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $9.13M | -54.6% | — | — |
| LTM Mar 2026 | $3.48M | -33.4% | — | 0.9% | |
| Peer median (excluding KNSA) | $34.27M | +8.7% | +19.9% | 99.8% | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (157.92M) | 183.36M | 14.08M | (43.19M) | (43.19M) |
| Depreciation & Amortization | 2.36M | 2.4M | 2.34M | 1.7M | 1.55M |
| Deferred Income Tax | 11K | (185.5M) | (33.79M) | 8.13M | 8.13M |
| Stock-Based Compensation | 25.17M | 25.12M | 27.15M | 30.69M | 30.69M |
| Change in Working Capital | 689K | (22.58M) | 1.35M | 24.81M | 51.63M |
| Accounts Receivables | (3.91M) | (16.33M) | (950K) | (20.46M) | 26.13M |
| Inventory | (3.68M) | (17.92M) | (9.52M) | 4.76M | 4.76M |
| Accounts Payables | 1.37M | 6.03M | 347K | (6.31M) | (6.31M) |
| Other Working Capital | 6.91M | 5.65M | 11.48M | 46.82M | 27.05M |
| Other Non-Cash Items | 3.4M | 2.99M | 2.17M | 3.55M | (23.13M) |
| Operating Cash Flow | (126.3M) | 5.81M | 13.3M | 25.69M | 25.69M |
| Capital Expenditures | (20.42M) | (105K) | (130K) | (277K) | (277K) |
| Acquisitions (Net) | 0 | 0 | 0 | 25K | 0 |
| Purchases of Investments | (157.25M) | (135.86M) | (204.93M) | (202.01M) | (202.01M) |
| Sales of Investments | 306.3M | 127.8M | 175.51M | 239.94M | 239.94M |
| Other Investing Activities | (20M) | 91K | 0 | 0 | 25K |
| Investing Cash Flow | 128.64M | (8.08M) | (29.56M) | 37.67M | 37.67M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.89M | 3.42M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (2.21M) | (4.98M) | (7.73M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (901K) | 3.7M | 17.25M | 20M |
| Financing Cash Flow | 5.89M | 2.52M | 1.5M | 12.27M | 12.27M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.22M | 245K | (14.76M) | 75.63M | 75.63M |
| Free Cash Flow | (146.71M) | 5.7M | 13.17M | 25.41M | 25.41M |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.